Morphological and functional changes in the dialysed peritoneal cavity: Impact of more biocompatible solutions

Nephrology Dialysis Transplantation

Volumn 17, Issue SUPPL. 3, 2002, Pages 12-15

  Devuyst, Olivier ^a   Topley, Nicholas ^b   Williams, John D ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Aquaporin; Membrane morphology; NO; Peritoneal dialysis; Vasculopathy

Indexed keywords

AQUAPORIN; ENZYME; NITRIC OXIDE;

ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; FLUID TRANSPORT; FUNCTIONAL MORPHOLOGY; HUMAN; MEMBRANE STRUCTURE; PERITONEAL CAVITY; PERITONEAL DIALYSIS; PERITONEUM; PRIORITY JOURNAL; PROTEIN INTERACTION; TREATMENT FAILURE; ULTRAFILTRATION; VASCULAR DISEASE;

EID: 0036242468     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.suppl_3.12     Document Type: Article

References (40)

1. What really happens to people on long-term peritoneal dialysis?
2. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis
3. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients
4. Functional longevity of the human peritoneum: How long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study
5. Peritoneal sclerosis in chronic peritoneal dialysis patients: Analysis of clinical presentation, risk factors and peritoneal transport kinetics
6. Conventional and newer PD solutions
7. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis
8. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration
9. Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure
10. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis
11. Ultrastructural studies on the peritoneum with special reference to chronic ambulatory peritoneal dialysis
12. Morphology of the peritoneum in CAPD
13. Peritoneal morphology on maintenance dialysis
14. Peritonitis during continuous ambulatory peritoneal dialysis
15. Ultrastructural morphology of the peritoneum: New findings and speculations on transfer of solutes and water during peritoneal dialysis
16. Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis
17. The morphology of the human peritoneum in CAPD patients
18. Pathophysiology of peritoneal membrane failure
19. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis
20. Morphological changes in the peritoneal membrane of patients with renal disease
21. Peritoneal physiology-impact on solute and fluid clearance
22. Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis
23. The nitric oxide donor nitroprusside intraperitoneally affects peritoneal permeability in CAPD
24. Aquaporin-1 and endothelial nitric oxide synthase expression in capillary endothelia of human peritoneum
25. Pathophysiological roles of nitric oxide in inflammation
26. Expression of aquaporin-1 in a long-term peritoneal dialysis patient with impaired transcellular water transport
27. Nitric oxide inhibits aquaporin-1 water permeability through interaction on cysteine
28. Biocompatibility of peritoneal dialysis solutions and host defense
29. Membrane longevity in peritoneal dialysis: Impact of infection and bio-incompatible solutions
30. Cytotoxicity of peritoneal dialysis fluid-is it related to glucose breakdown products
31. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD
32. Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds
33. In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD
34. Bicarbonate lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFα secretion
35. Bicarbonate lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels
36. Continuous dialysis with bicarbonate lactate-buffered peritoneal dialysis fluids results in a long-term improvement in ex vivo peritoneal macrophage function
37. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate lactate-based peritoneal dialysis solutions
38. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products
39. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: Prospective cross-over study with a three-compartment bag
40. In vivo exposure to bicarbonate lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function